Company profile
Citius Pharmaceuticals, Inc.
NASDAQ: CTXR · Healthcare · Biotechnology
#1045 of 1,418 Healthcare companies by revenue41st-percentile growth
EA Score
42DFH 39DQ 42GM 52SS 46
v0.1 · 65/100 weight · provisional
↑ growth stability, balance-sheet leverage · ↓ operating margin, net margin
Methodology →Revenue TTM
$7.1M
Rev growth YoY (TTM)
+4456.8%
Net income (FY)
-$39.7M
Employees
23
as of 2026-08-23
Market cap
$6.7M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$90.0k$90.0k2022
Net income-$39.7M-$39.7M2025
Operating income-$38.5M-$38.5M2025
Total assets$130.9M$130.9M2025
Liabilities$53.4M$53.4M2025
Equity$67.6M$67.6M2025
Revenue trend
FY2012 – FY2022 · USD
FY12
FY13
FY19
FY19
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Citius Pharmaceuticals, Inc.’s revenue?
Citius Pharmaceuticals, Inc. booked $90.0k in FY2022 revenue, growing 0.0% year over year — about the middle of the pack among Healthcare companies we track, at a -44155.9% net margin.
Peers · Healthcare
Therapeutic Solutions International, Inc.——Allied Corp.——Actinium Pharmaceuticals, Inc.28DAIM ImmunoTech Inc.36DZecotek Photonics Inc.——Black Bird Biotech, Inc.——Neighbors
Union →Key facts
CEOLeonard L. Mazur
SectorHealthcare
IndustryBiotechnology
HeadquartersCranford, NJ
ExchangeNASDAQ: CTXR
Employees23
IPO date2014-10-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.